What's driving Pharmeasy Unlisted Share Price 40% Rise In 7 days?

TL;DR

PharmEasy’s unlisted share price rose 40% in a week, from Rs. 6.30 to Rs. 8.82. The jump comes as API Holdings shows improvement in revenue, profitability, cash flow and debt levels, while the Docon merger strengthened its Thyrocare ownership. The focus now is on whether this growth can continue.

__________

PharmEasy's unlisted share price has moved sharply in just one week, rising from Rs. 6.30 to Rs. 8.82 per share. That works out to a 40% increase, putting API Holdings back in focus in the unlisted market. But the bigger question is not just how much the price has moved. What changed at API Holdings to support this sudden rise? Here's what has changed.

PharmEasy Unlisted Share Price Moves From Rs. 6.30 to Rs. 8.82

PharmEasy’s share price rose from Rs. 6.30 to Rs. 8.82, an increase of Rs. 2.52, or about 40% in one week. The timing, though, could be interesting. API Holdings’ FY26 Annual Report was sent to shareholders on September 8, 2026, bringing its latest financial performance into focus just before the recent price move. Possible explanations for this increase are:

1. FY26 Shows a Clear Improvement in the Business

Source: API Holding Annual Report

Revenue from operations increased from Rs. 5,872.2 Cr to Rs. 6,618.5 Cr in FY26, a growth of about 12.7%. At the same time, the company sharply reduced its losses and improved its operating performance. The key is that the improvement is not limited to revenue. API Holdings has expanded its business, reduced losses and improved cash generation.

Losses Have Fallen Sharply

API Holdings' consolidated loss declined to Rs. 520.3 Cr in FY26 from Rs. 1,572.4 Cr in FY25. That is a significant reduction, although the company is still loss-making at the consolidated net-profit level. So, the better way to describe FY26 is as an operating improvement.

2. API Holdings Moves From EBITDA Loss to Profit

API Holdings moved from an EBITDA loss of around Rs. 231 Cr in FY25 to positive EBITDA of Rs. 62.5 Cr in FY26. The improvement shows that API Holdings is better positioned to control costs as it scales revenue. The company has been focusing on cost optimisation, improving gross margins, better utilisation of infrastructure, and moving away from lower-quality or low-margin revenue. Hence, PharmEasy could focus more on building a business that grows while improving its bottom line. However, positive EBITDA should not be confused with net profit. API Holdings still reported a consolidated loss of Rs. 520.3 Cr in FY26.

3. The Docon Merger Alters API Holdings’ Composition

Docon Technologies’ merger with API Holdings received NCLT approval and became effective in September 2026.  Following the merger, Docon’s 51.02% stake in Thyrocare was transferred directly to API Holdings. The change was subsequently reflected in Thyrocare’s regulatory filings, with API Holdings becoming the direct holder of the stake.

4. API Holdings Clears Out Remaining Debt

API Holdings completed its debt repayment plan in August 2026 by repaying its outstanding Rs. 1,050 Cr NCD facility. The repayment was made by the company through internal accruals and proceeds from the sale of around 9.9% of Thyrocare Technologies.(Source:Moneycontrol)

The repayment reduced API Holdings’ interest obligations and also released the pledge over its remaining Thyrocare shares. Importantly, the company repaid the debt and retained a majority stake in Thyrocare.

5. Positive Cash Flow is a Sign of Greater Progress

API Holdings' cash flow from operating activities turned positive at Rs 77.2 Cr in FY26 compared with an outflow of Rs 210.9 Cr in FY25. This means the company’s operations generated cash over the year, instead of burning through it. This is especially true for API Holdings along with the improvement in EBITDA, as it signals that the better operating performance was also accompanied by an improvement in cash generation. Going forward, the key metric will be whether the company can sustain positive operating cash flow while continuing to grow.

What to Watch After the Recent PharmEasy Share Price Surge

The PharmEasy share price has risen 40%, from Rs. 6.30 to Rs. 8.82 in one week, making the next phase more important than the move itself. With the recent financial and balance-sheet changes already covered, the focus now shifts to execution. Whether API Holdings can sustain its improved operating performance, move closer to pre-tax profitability excluding Thyrocare, and meet the FY27 milestones management outlined for a potential future listing route. Rahul Guha has said the group would need to be debt-free and pre-tax profitable, excluding Thyrocare by the end of FY27 before considering a listing or reverse-merger route.